Nature Medicine, Published online: 07 January 2025; doi:10.1038/s41591-024-03428-2
A phase 1/2 clinical trial of a new device-assisted therapy in Parkinson’s disease revealed that intracerebroventricular administration of anaerobic dopamine was safe and significantly reduced l-dopa-related complications.
